1. Home
  2. PXED vs GLUE Comparison

PXED vs GLUE Comparison

Compare PXED & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PXED

Phoenix Education Partners Inc.

N/A

Current Price

$31.78

Market Cap

1.2B

Sector

Real Estate

ML Signal

N/A

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$23.33

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PXED
GLUE
Founded
1976
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
PXED
GLUE
Price
$31.78
$23.33
Analyst Decision
Buy
Buy
Analyst Count
7
2
Target Price
$45.00
$19.50
AVG Volume (30 Days)
142.8K
1.2M
Earning Date
01-13-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
3.51
0.25
Revenue
$1,007,192,000.00
$181,538,000.00
Revenue This Year
$4.15
$84.02
Revenue Next Year
$4.86
N/A
P/E Ratio
$9.74
$63.42
Revenue Growth
6.02
1112.27
52 Week Low
$23.52
$3.50
52 Week High
$47.08
$19.17

Technical Indicators

Market Signals
Indicator
PXED
GLUE
Relative Strength Index (RSI) N/A 72.64
Support Level N/A $13.69
Resistance Level N/A $17.81
Average True Range (ATR) 0.00 1.55
MACD 0.00 0.21
Stochastic Oscillator 0.00 83.64

Price Performance

Historical Comparison
PXED
GLUE

About PXED Phoenix Education Partners Inc.

Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: